AI MARKET SCANNING

BioAtla, Inc.

📅 Next Catalyst: Nov 11, 2026 (🌙 Close) 🏛️ NASDAQ 📁 Healthcare 🏭 Biotechnology
AVG HISTORICAL GAP +1.24%
MAX GAP RECORD -13.49%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $BCAB
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Nov 11, 2026 Earnings Release 2026-11-11 (UNDETERMINED) 🔮 UPCOMING 🔒
Aug 11, 2026 Earnings Release 2026-08-11 (AFTER CLOSE (16:00))
+1.43%
Nov 13, 2025 Earnings Release 2025-11-13 (AFTER CLOSE)
+6.82%
Aug 07, 2025 Earnings Release 2025-08-07 (AFTER CLOSE)
-3.68%
Mar 28, 2025 Earnings Release 2025-03-28 (BEFORE OPEN)
-13.49%
Nov 07, 2024 Earnings Release 2024-11-07 (AFTER CLOSE)
+1.80%
Aug 08, 2024 Earnings Release 2024-08-08 (AFTER CLOSE)
+2.04%
May 14, 2024 Earnings Release 2024-05-14 (AFTER CLOSE)
+10.34%

VOLATILITY & GAP BIAS

AVG GAP MOVE 4.6%
Bullish Gaps (8)
Bearish Gaps (3)
Neutral / Flat (1)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $BCAB

EXECUTIONS0 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
Radar monitoring: awaiting next setup.
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗